Price Alert

Tekla Life Sciences Inves... (HQL)

NYSE: HQL · Real-Time Price · USD

16.46

0.25 (1.54%)

At close: Oct 15, 2025, 3:59 PM

16.45

-0.06%

After-hours: Oct 15, 2025, 06:21 PM EDT

Tekla Life Sciences Investors Statistics

Share Statistics

Tekla Life Sciences Investors has n/a shares outstanding. The number of shares has increased by 5.56% in one year.

Shares Outstanding	n/a
Shares Change (YoY)	5.56%
Shares Change (QoQ)	0%
Owned by Institutions (%)	29.17%
Shares Floating	26.94M
Failed to Deliver (FTD) Shares	241
FTD / Avg. Volume	0.17%

Short Selling Information

The latest short interest is 38.49K, so 0% of the outstanding shares have been sold short.

Short Interest	38.49K
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1

Valuation Ratios

The PE ratio is 4.96 and the forward PE ratio is null. Tekla Life Sciences Investors's PEG ratio is 0.02.

PE Ratio	4.96
Forward PE	n/a
PS Ratio	4.88
Forward PS	n/a
PB Ratio	0.92
P/FCF Ratio	0
PEG Ratio	0.02

Financial Ratio History

Enterprise Valuation

Tekla Life Sciences Investors has an Enterprise Value (EV) of 423.17M.

EV / Sales	4.88
EV / EBITDA	4.96
EV / EBIT	0
EV / FCF	0

Financial Position

The company has a current ratio of 0.32, with a Debt / Equity ratio of 0.

Current Ratio	0.32
Quick Ratio	0.32
Debt / Equity	0
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	0

Financial Efficiency

Return on Equity is 18.56% and Return on Invested Capital is 18.01%.

Return on Equity	18.56%
Return on Assets	18.52%
Return on Invested Capital	18.01%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	undefined
Asset Turnover	0.19
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	0%

Stock Price Statistics

The stock price has increased by 8.57% in the last 52 weeks. The beta is 0.75, so Tekla Life Sciences Investors's price volatility has been higher than the market average.

Beta	0.75
52-Week Price Change	8.57%
50-Day Moving Average	14.38
200-Day Moving Average	13.33
Relative Strength Index (RSI)	77.74
Average Volume (20 Days)	142,612

Income Statement

In the last 12 months, Tekla Life Sciences Investors had revenue of 86.69M and earned 85.3M in profits. Earnings per share was 3.04.

Revenue	86.69M
Gross Profit	86.69M
Operating Income	85.3M
Net Income	85.3M
EBITDA	85.3M
EBIT	85.3M
Earnings Per Share (EPS)	3.04

Full Income Statement

Balance Sheet

Cash & Cash Equivalents	n/a
Total Debt	n/a
Net Cash	n/a
Retained Earnings	44.13M
Total Assets	411.34M
Working Capital	n/a

Full Balance Sheet

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	0

Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of 98.4% and 98.4%.

Gross Margin	100%
Operating Margin	98.4%
Pretax Margin	98.4%
Profit Margin	98.4%
EBITDA Margin	98.4%
EBIT Margin	98.4%
FCF Margin	n/a

Dividends & Yields

HQL pays an annual dividend of $2.31, which amounts to a dividend yield of 13.16%.

Dividend Per Share	$2.31
Dividend Yield	13.16%
Dividend Growth (YoY)	20.51%
Payout Ratio	-481.25%
Earnings Yield	20.16%
FCF Yield	0%

Dividend Details

Analyst Forecast

Currently there are no analyst rating for HQL.

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	$15.2
Lynch Upside	-6.29%
Graham Number	33.47
Graham Upside	106.35%

Scores

Altman Z-Score	18.31
Piotroski F-Score	3